Therefore, combining TGF‐β inhibitors with ICIs has been proposed to enhance the immune‐activating effects of ICIs on excluded phenotype tumors by promoting CD8+ T cell infiltration into tumor regions through the elimination of CAFs.50, 51. Here, TGFB1 is linked to neoplasm.